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Heart failurea b s t r a c t
Background: Fibroblast growth factor 23 (FGF23) is a regulator of mineral metabolism, that has been
linked to myocardial remodeling including development of left ventricular (LV) hypertrophy and myocar-
dial fibrosis. The aim of this study was to investigate the relationship between intact FGF23 (iFGF23),
myocardial infarct size and LV remodeling following a first acute ST-elevation myocardial infarction
(STEMI).
Methods and results: Forty-two consecutive patients with first-time STEMI, single vessel disease, success-
fully treated with primary percutaneous coronary intervention were included. Cardiac magnetic reso-
nance (CMR) imaging was performed at day 2, 1 week, 2 months and 1 year post MI, and blood
samples were drawn at admittance and at the same time points as the CMRs. The cohort was divided
according to the presence or not of heart failure post MI. In the total cohort, iFGF23 (mean ± SD) was sig-
nificantly lower at day 0 (33.7 ± 20.6 pg/ml) and day 2 (31.5 ± 23.4 pg/ml) compared with a reference
interval based on 8 healthy adults (43.9 pg/ml ± 19.0 pg/ml). iFGF23 increased to normal levels (55.8 ±
23.4 pg/ml) seven days post MI. In the subset of patients with signs of acute heart failure, FGF23 was
higher at all measured timepoints, reaching significantly higher FGF23 levels at 2 months and 1 year fol-
lowing revascularization.
Conclusion: There was a reduction in iFGF23 levels during the acute phase of MI, with a normalization at
seven days following revascularization. During one-year follow-up, there was a gradual increase in
iFGF23 levels in patients with heart failure.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fibroblast growth factor 23 (FGF23) is a circulating phospha-
turic molecule secreted mainly from osteocytes in bone, acting
on the kidney and parathyroid glands to regulate the phosphate-
homeostasis and vitamin D metabolism. FGF23 is also implicatedin the sodium-phosphate cotransport in the proximal tubule in
the kidney. Circulating FGF23 increases early in the development
of chronic kidney disease (CKD), and FGF23 has emerged a power-
ful predictor of adverse outcomes in patients with CKD, and a
potential target for medical therapy in these disorders [1–3].
Several studies have also demonstrated an association between
high levels of FGF23, cardiovascular events and all-cause mortality
irrespective of the presence of CKD [3–6]. To this end, the
pathophysiological role of FGF23 in cardiac disease has not been
established. A recent study has suggested that cardiac myelofi-
broblasts are the main source of FGF23 within the myocardium
[7], and persistent elevation of FGF23 has been associated with
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(LV) hypertrophy and myocardial fibrosis [8].
In contrast to chronic FGF23 elevation, the role of FGF23 in the
setting of acute myocardial damage, such as myocardial infarction
(MI) is less clear. FGF23 may induce positive ionotropic effects
through alterations in intracellular calcium handling in cardiomy-
ocytes [9]. This may potentially contribute to a compensatory
enhancement of contractility in non-infarcted myocardium follow-
ing acute MI. In animal models, FGF23 is upregulated in myofibrob-
lasts following MI, suggesting a potential physiologic role of FGF23
in the acute phase of a MI [7]. Simultaneously, transforming
growth factor-b (TGF-b) was found to be the strongest inhibitor
of FGF23 expression, indicating the presence of counter-
regulatory mechanisms attenuating the effects of FGF23. More-
over, activated macrophages and dendritic cells express high levels
of FGF23, linking this mediator to inflammation. Hence, current
data suggest that FGF23 reflects different aspects of myocardial
injury and healing at different time-points following acute MI.
However, although elevated FGF23 was found to be negatively
associated with adverse outcomes and heart failure after MI
[5,10], the impact of FGF23 on post-MI remodeling is still unclear.
In particular, few studies have addressed the dynamic relationship
between myocardial remodeling and FGF23 following acute MI.
The aim of this study was therefore to investigate the time-
dependent changes in FGF23 and the relationship between circu-
lating FGF23 levels and MI size, LV remodeling and systemic
biomarkers of inflammation and collagen turnover following MI.2. Materials and methods
2.1. Study population and study design
This is a single center observational study including patients
with a first-time ST-elevation MI (STEMI) due to an occlusion of
a single, large coronary artery, successfully revascularized with pri-
mary percutaneous coronary intervention (pPCI), assessed by car-
diac magnetic resonance (CMR) at 4 time-points during the first
year following infarction: at 2 days, 1 week, 2 months and 1 year.
The CMR examinations were used to assess infarct size and left
ventricular (LV) volumes and ejection fraction (LVEF). Blood sam-
ples were drawn at admittance (before revascularization), and at
the same time points as the CMRs.
Inclusion and exclusion criteria have previously been described
[11]. In brief 42 patients with their first-time STEMI (typical chest
pain and ST-elevations on ECG) were recruited if they had acute
proximal/ mid-occluded single vessel disease and went through a
successful revascularization (pPCI) defined as TIMI 3 flow, and no
significant residual stenosis. Patients were excluded if they had
evidence of previous MI based on history, ECG or angiography, or
if they had more than single vessel disease on angiography or
CMR. Patients were excluded if they had co-morbidities such as
chronic atrial fibrillation, malignancies, autoimmune disorders or
infectious diseases, as well as reinfarction during the first week
or contraindications against CMR. All patients were treated accord-
ing to standard percutaneous coronary intervention (PCI) proce-
dure, with aspirin, clopidogrel, heparin and statins. Post-MI
patients were treated according to current guidelines with ACE
inhibitor/angiotensin receptor blockers, diuretics and beta-
blockers. They were treated with an aldosterone antagonist if indi-
cated, in accordance with the criteria used in the EPHESUS study.
Patients with left ventricular dysfunction as documented by a left
ventricular ejection fraction of 40 percent or lower, and heart fail-
ure as documented by the presence of pulmonary rales, chest
radiography showing pulmonary venous congestion. In patients
with diabetes who met the criteria for left ventricular dysfunction2
after acute myocardial infarction, symptoms of heart failure did
not have to be demonstrated, since such patients have an increased
risk of cardiovascular events similar to that of nondiabetic patients
with symptoms of heart failure.[12]. None of our 8 patients receiv-
ing aldosterone antagonist, were started because of diabetes. They
all had EF < 40% and clinical signs of heart failure. We divided the
cohort according to the presence or absence of heart failure post
MI, using +/- indication for aldosterone antagonist to divide the
group.
The Regional Ethics Committee at the University of Bergen
approved the study, and all the patients gave their written
informed consent prior to inclusion. The investigation was per-
formed according to the principles in the Declaration of Helsinki.
2.2. Cardiac magnetic resonance imaging
The CMR images were ECG-gated and obtained during breath
holding. Patients were scanned in a supine position by a 1.5 T
whole body scanner (InteraTM R10, Philips Medical Systems, Best,
The Netherlands) using a dedicated cardiac coil. Resting LV func-
tion was determined with cine images using a steady-state free
precession technique. For first-pass perfusion, a turbo field echo
sequence with three short-axis slices per heartbeat (prospective
triggering) and a selective saturation recovery prepulse was used.
Gadolinium-based contrast agent (OmniscanTM, Amersham Health,
Little Chalfont, UK) was given at a dose of 0.075 mmol/kg. Immedi-
ately following the completion of the first-pass imaging, another
0.175 mmol/kg of contrast agent was infused, and 10–15 min fol-
lowing the latter infusion-delayed hyper enhancement images
were acquired. All post- processing was performed on the View
ForumTM Software (Philips Medical Systems, Best, The Netherlands)
in a random, blinded fashion. Assessment of body surface indexed
end-diastolic (LVEDVi), end-systolic (LVEDVSi), and EF was done
by short-axis volumetry. Infarct size was assessed manually with
plainimetry on each short-axis slice by delineating the hyper
enhanced area from the non-enhanced myocardium [13].
2.3. Blood sampling protocol
Venous blood samples were collected on admission to the hos-
pital, immediately prior to PCI, and 2 days, 7 days, 2 months and
1 year following MI. The pyregen-free blood collection tubes were
immediately immersed in melting ice (ethylenediaminetetraacetic
acid-containing tubes, plasma) or placed in room temperature
(tubes without any additives, serum) and centrifuged within
20 min at 2500g for 20 min to obtain platelet-poor plasma, or cen-
trifuged at 1000g for 10 min after coagulation (serum). All samples
were stored at 50 C and thawed only once. Biomarkers were
analyzed in one run, after the study was completed.
2.4. Biomarkers
Plasma iFGF23 was measured by commercially available
enzyme-linked immunosorbent assay (ELISA) kits from Immu-
topics International, San Clemente, CA, USA. Freshly thawed sam-
ples were measured in duplicates, and the reproducibility of the
method monitored by analyzing 4 aliquots of a control with each
assay. Intra- and inter-assay coefficient of variation for iFGF23
was <8%. The reference interval for iFGF23 based on 8 healthy
adults measured in the same laboratory was on average 43.9 pg/
ml (±19.0 pg/ml). Serum levels of connective tissue growth factor
(s-CTGF) were determined by a sandwich enzyme-linked
immunosorbent assay (ELISA) [14]. The concentration of trans-
forming growth factor b1 (TGF-b1) was measured by EIA (R&D Sys-
tems) [15]. Serum 25(OH) vitamin D were quantified by liquid–
liquid extraction, derivatization with 4-phenyl-1,2,4-triazoline-3,
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analysis by liquid chromatography coupled with tandem mass
spectrometry detection [16]. In this study, levels of serum 25
(OH) vitamin D are termed deficient < 30 nmol/l (<12 ng/mL),
insufficient at 30–50 nmol/L (12–20 ng/mL), sufficient at
>50 nmol/L (>20 ng/mL) [17].
Amino-terminal propeptide of procollagen type I (PINP), amino-
terminal propeptide of procollagen type III (PIINP) and carboxyter-
minal type I telopeptid (CITP) as markers of extracellular matrix
(ECM) remodelling were analysed using a radioimmunoassay from
Orion Diagnostica (Finland). The lower detection limit was 2.0 ng/
mL for PINP, 0.20 ng/mL for PIIINP and 0.50 ng/mL for CITP
respectively.
C-reactive protein (CRP) concentrations were measured by a
particle enhanced immunoturbidimetric method with the use of
Roche ModularP automated clinical chemistry analyser (Roche
Diagnostics, Basel, Switzerland) and reagents of Tina-quant C-
reactive protein (latex) assay (Roche Diagnostics), reference range
0–7 mg/L. Creatininewas analysed on Roche Modular P, enzymatic
colorimetric assay (CREA plus), (ref.range 60–105 mmol/L for men
and 45–90 mmol/L for women), calcium was analyzed on Roche
Modular P using colorimetric assay (ref.range 2.15–2.55 mmol/L),
inorganic phosphorus (phosphate) was analyzed on Roche modu-
lar P (ref.range 0.85–1.44 mmol/L). Troponin T (TnT) concentra-
tions were measured on Roche Elecsys 2010 (Roche Diagnostics),
with the immunoassay Troponin T (Roche Diagnostics), using
biotinylated monoclonal troponin T-specific antibody and a mono-
clonal troponin T-specific antibody labelled with ruthenium form-
ing a sandwich complex, reference range  14 mg/L. N-terminal pro
B-type natriuretic peptide (NT-proBNP) was measured with a
Roche Diagnostics NT-proBNP assay on an Elecsys 2010 analyser,
reference range 0–100 pg/mL. Plasma intact parathyroid hormone
(iPTH) was determined using an intact PTH assay from Abbot Diag-
nostics, analyzed on Architect i2000SR (Abbott Diagnostics), refer-
ence range 1.6–8.5 pmol/L.2.5. Statistical analysis
Baseline characteristics were assessed by standard descriptive
statistics. Data are expressed as mean ± SD for normally distributed
data or median and range for non-normally distributed data. Area
under the curve (AUC) was calculated for each biomarker at differ-
ent time points during 1-year follow-up, and correlations were
measured cumulatively. ANOVA was used to test for differences
between the variables measured at multiple time points, with Bon-
ferroni post-hoc testing where appropriate. Univariate correlations
were performed using non-parametric methods (Spearman). Non-
parametric tests (Mann-Whitney U, Kruskal-Wallis) were used to
test for differences between groups. A two-tailed p-value of
<0.05 was considered significant. SPSS version 24.0 was used for
statistical analysis.3. Results
3.1. iFGF and markers of extracellular matrix turn over following MI
The mean (SD) age was 58 (12) years, 34 males and 8 females,
Mean (SD) BMI was 27.2 (3.4), mean (SD) blood pressure was sys-
tolic 140 (27) mmHg, and diastolic 84 (20) mmHg. 10 patients
were previously treatment for hypertension, 3 were diabetic, 20
were current smokers. Mean (SD) creatinine levels were 74.9
(17.4) mmol/L.
Several significant patterns were revealed comparing the pat-
tern during follow-up in MI patients. First, iFGF23 was significantly
lower day 0 and day 2 compared with the levels measured in3
healthy adults, with a significant increase in concentrations during
follow-up reaching levels comparable/higher than healthy adults
on day 7 with the highest concentrations at 1 year, Fig. 1.
Second, type I collagen degradation marker (CITP) increased sig-
nificantly from day 0 to day 2, and remained elevated throughout
the observation period indicating a prolonged increased collagen
type I degradation following MI. Third, in contrast to this pattern,
type I collagen production marker (PINP) showed a late, significant
increase from day 0 reaching the highest level at 1 year, suggesting
a slower increase in collagen type I synthesis. Fourth, collagen type
III production marker (PIIINP) showed a rapid increase during the
first week, with persistent elevation for the rest of the observation
period, suggesting a rapid increase in type III collagen synthesis.
Finally, there was no significant changes during follow-up in 25
(OH) vitamin D, CTGF, TGF-b, creatinine, calcium, phosphate and
PTH levels, Table 1. There was no correlation between iFGF23
levels and the other biomarkers at any time-points. However, there
was a strong correlation between the AUC of FGF23 and CTGF dur-
ing the 1-year follow-up (r = 0.53, p < 0.01).
3.2. Cardiac magnetic resonance imaging following MI
CMR findings are listed in Table 1. In the whole group of
patients there was a significant reduction in infarct size from
16.1 to 9.8 g/m2 (p < 0.001) and myocardial mass from 66.0 g/m2
to 58.3 g/m2 (p = 0.002) from day 1 to 1 year post MI. LV ejection
fraction (EF) increased from 47.2% at baseline to 52.7% at one year
follow-up (p < 0.001). Left ventricular end systolic volume (LVESVi)
and left ventricular end diastolic volume (LVEDVi) did not change
significantly, Table 1. In the group as a whole, there was no corre-
lation between iFGF23 levels and the CMR findings at any time-
points.
3.3. FGF23 levels in patients with impaired post-MI myocardial
function in the acute phase
As previously described in methods, the studied cohort was
divided according to the presence or absence of LV dysfunction
or heart failure during the acute course of the MI. A total of 8
patients had LVEF < 40% and signs of acute heart failure. These
patients had larger infarct sizes, lower EF and increased end
diastolic- and end systolic volume on MRI, Fig. 2.
All the patients with heart failure (n = 8) were treated with
aldosterone antagonists following revascularization. iFGF23 levels
were higher at all time-points in this group compared with the
other patients (n = 34), and significantly higher at day 60 (70.6 ± 2
3.7 pg/ml vs 51.7 ± 21.2 pg/ml, p = 0.025) and 1 year (83.7 ± 41.
8 pg/ml vs 52.0 ± 18.9 pg/ml, p = 0.019) following MI, Fig. 3. Abso-
lute change in iFGF23 levels from baseline to 1 year follow up was
40.0 pg/ml in the heart failure group, and 21.0 pg/ml in the no
heart failure group.
In the patients with acute heart failure, there was a significant
correlation between the AUC of the iFGF23 concentrations 7 days
post MI and CMR findings on day 7, with LVEF (r = 0.76,
p < 0.05), infarcted mass (r = 0.75, p < 0.05) and infarct size in per-
cent of LV mass (r = 0.71, 0 < 0.05).4. Discussion
In the present study we show a significant reduction in sys-
temic iFGF23 levels in the very early phase of acute MI followed
by a gradual increase during follow-up reaching the highest levels
after one year. Notably, patients with heart failure during the acute
phase following MI had a significantly higher iFGF23 concentration
from day 7 post MI. In contrast, no direct relationship was found
Fig. 1. iFGF23 measurements at the different timepoints, Mean ± SD in red. Y-axis:
iFGF23, X-axis: time, *p < 0.05, compared with reference interval of 43.9 pg/ml
(±19.0 pg/ml). (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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function measured by cardiac MRI. There was no correlation with
other systemic markers of MI, inflammation, collagen turnover or
LV remodeling. Taken together, the present findings suggest that
the early suppression of systemic iFGF23 levels in the acute phase
of MI is not directly related to the size of myocardial injury or
myocardial reperfusion. Interestingly, the largest reduction in
iFGF23 levels occurred in the group of patients without evidence
of acute LV dysfunction, potentially suggesting that the iFGF23
reduction in the acute phase of MI may represent a physiological
response to counteract myocardial failure.
Our findings are in accordance with clinical data from Taka-
hashi et al who found lower levels of FGF23 in MI patients com-
pared with controls, looking at 44 patients with acute MI who
underwent PCI. They followed 22 patients with echocardiography
6 months post MI and found an association between high FGF23
and low EF at 6 months [18]. Our study extends these observations
to a larger population and a longer duration of one year of follow-Table 1
Biomarkers and MRI results.
Laboratory parameters Day 0 Day 2 D
iFGF23 (pg/ml) 33.4 ± 18.5 31.5 ± 23.4 5
25 (OH)D 51.9 ± 19.7 48.6 ± 18.1 5
(nmol/l)
CITP (ng/mL) 3.0 ± 1.4 4.1 ± 1.6 4
PINP (ng/mL) 37.9 ± 17.0 37.9 ± 16.4 3
PIIINP (ng/mL) 4.1 ± 1.3 4.9 ± 1.7 4
CRP (mg/L) 5.5 ± 7.5 46.1 ± 45.7 1
TnT (mg/mL) 0.16 ± 0.24 7.14 ± 5.18 4
TGF-b (ng/mL) 19.7 ± 7.2 21.1 ± 6.6 2
CTGF (ng/mL) 134.3 ± 66.3 140.8 ± 81.4 1
NT-proBNP 12.9 (2.5–345.7) 157.0 (24.7–1556.0) 5
CMR
Myocardial mass (g/m2) – 66.0 ± 10.1 6
Infarcted myocardium (g/m2) – 16.1 ± 7.4 1
Infarct size (%) – 24 ± 9 2
LVEF – 47.2 ± 9.0 5
LVEDVI (mL/m2) – 90.0 ± 13.6 9
LVESVI (mL/m2) – 48.5 ± 12.8 4
Normally distributed values are expressed as mean ± SD.
iFGF23 = intact fibroblast growth factor 23, 25 (OH)D = 25-hydroxyvitamin D, CITP = C-
procollagen, PIINP = amino terminal propeptide of type III procollagen, CRP = C-reactive p
tissue growth factor, NT-proBNP = N-terminal pro B-type natriuretic peptide, EF = ejec
ventricular end systolic volume per m2.
4
up, using cardiac MRI to quantify the size of MI and function; also
including a large number of biomarkers of collagen turnover.
We found increased FGF 23 levels in subjects with acute heart
failure or LV dysfunction following acute MI as also have been
reported by others. Fuernau et al. measured FGF23 in patients with
acute MI complicated by cardiogenic shock [19]. They found non-
survivors to have significantly higher FGF23 levels at 1, 2 and
3 days post MI. However, the negative prognostic association of
FGF23 with adverse outcomes was only significant in patients with
creatinine levels above median at admittance [19]. Poss et al. found
significantly increased levels of FGF23 in patients with cardiogenic
shock, compared with patients with uncomplicated MI [8]. Reindl
et al. looked at 88 patients with acute MI who also underwent
PCI. They found higher FGF23 levels in patients who developed
LV remodeling (13%) on MRI, examined 2 days and 4 months post
MI [20]. Our findings are in line with these previous reports,
demonstrating higher systemic FGF23 levels in subjects with the
clinically worst prognosis. However, our study adds to these find-
ings demonstrating that there is no direct relationship between
systemic levels of FGF23 in the acute phase of an MI and the infarct
size, LV mass, LV volumes or LVEF assessed by CMR.
Our findings are in apparent contrast to the increasing number
of publications suggesting that iFGF23 have direct myocardial
actions that may be relevant in the acute MI [7,21]. FGF23 has been
shown to induce LV hypertrophy independently of the most com-
mon FGF23 receptor complex consisting of Klotho/ FGF23 receptor,
by activating FGF receptor 4 (FGFR4) and subsequently the cal-
cineurin/ nuclear factor of activated T cells (NFAT) signaling
in vivo and in vitro [22,23]. In situations with decreased FGF23
post MI, calcitriol levels increase leading to a blockade of the NFAT
signaling pathway. This is possibly a protective mechanism atten-
uating the development of LV hypertrophy and myocardial fibrosis.
It may be speculated that in large MIs, this downregulation is over-
turned into upregulation of FGF23 and enhanced development of
fibrosis post-MI with increased levels of local produced FGF23
and an upregulation of FGFR4 in the myocardium secondary to
inflammation [24].
In vitro data also indicate that FGF23 stimulate proliferation
and migration of fibroblasts essential to development of replace-
ment fibrosis necessary for normal scar healing and the prevention
of wound rupture [25]. In the acute phase a downregulation of
FGF23 might protect the heart from developing scarring and fibro-ay 7 Day 60 Day 365 p-value (ANOVA)
4.7 ± 23.1 55.3 ± 22.7 58.0 ± 27.3 <0.001
1.3 ± 19.1 51.7 ± 18.8 54.4 ± 19.6 0.641
.0 ± 1.8 4.4 ± 3.1 4.6 ± 2.5 0.006
7.7 ± 16.0 46.0 ± 19.3 57.1 ± 46.0 0.002
.9 ± 1.6 4.6 ± 1.3 4.9 ± 1.5 0.083
7.3 ± 26.2 2.2 ± 1.8 1.8 ± 2.1 <0.001
.25 ± 3.25 3.46 ± 2.83 3.13 ± 2.47 <0.001
3.3 ± 7.1 21.1 ± 6.4 22.0 ± 5.3 0.163
58.5 ± 183.3 163.7 ± 209.9 130.9 ± 71.6 0.749
5.4 (14.4–886.4) 34.9 (7.7–446.0) – <0.001
5.2 ± 10.2 59.8 ± 10.9 58.3 ± 12.5 0.002
3.7 ± 6.9 10.5 ± 6.5 9.8 ± 6.6 <0.001
1 ± 9 17 ± 8 16 ± 8 <0.001
0.2 ± 7.9 52.9 ± 9.5 52.7 ± 10.6 0.020
0.1 ± 15.5 89.6 ± 16.5 91.1 ± 21.9 0.996
5.9 ± 12.8 45.6 ± 16.8 44.9 ± 19.9 0.614
terminal telopeptide of type I collagen, PINP = Amino terminal propeptide of type I
rotein, TnT = troponine T, TGF-b = transforming growth factor-b, CTGF = connective
tion fraction, LVEDVI = left ventricular end diastolic volume per m2, LVESVI = left
Fig. 2. (A) Ejection fraction, (B) infarct size, (C) left ventricular end diastolic volume per m2, (D) left ventricular end systolic volume per m2 in patients without heart failure
and with heart failure on treatment with an aldosterone antagonist post MI expressed as mean (95% CI), *p < 0.05.
Fig. 3. FGF23 levels in patients without heart failure and with heart failure on treatment with an aldosterone antagonist post MI, mean and 95% CI. Y-axis: iFGF23
concentration, X-axis: time, *p < 0.05.
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PCɣ/C/NFAT signaling pathway for FGF23 in the myocardium [9].
Inflammation might be a mechanism linking FGF23 to cardiovascu-
lar disease [26]. It has been shown that FGF23 in cardiac fibrob-
lasts, is upregulated in systemic inflammation [24]. Herein we
found a significantly increased CRP (p < 0.001) at day 2 and day
7 post-MI, Table 1, but there was no significant difference between
CRP levels in the 2 groups of patients in our study, questioning the
link between FGF23 and inflammation in clinical MI.
Slavic et al have identified aldosterone as an important stimula-
tor of bony FGF23 transcription, where blockade with spironolac-
tone normalized serum FGF23 levels and bone transcription [27].
Serum aldosterone levels correlated with FGF23 in patients with
non-ischemic heart failure [28]. Aldosterone increased FGF23
levels in vitro as well as in mice treated with deoxycorticosterone
acetat (DOCA) leading to hypertension and end-organ damage [29].
These findings indicate that aldosterone stimulates bone-mediated
FGF23 synthesis. This is consistent with our findings where the
group of patients with heart failure, treated with an aldosterone
antagonist, had higher FGF23 compared with patients without
heart failure. The level of FGF23 might have been even higher in
these patients without treatment with an aldosterone antagonist.5. Strengths and limitations
The study explores a relatively small sample size, which makes
it susceptible to the impact of biological heterogeneity, but the trial
was designed with strict selection criteria to reduce the number of
confounders. The cohort represents a unique and homogenous
patient sample. When dividing into two groups based on the pres-
ence or absence of acute heart failure, we faced a power-problem
since the group with the additional treatment contained only 8
patients, meaning that the data provide trends more than statisti-
cally significant data.6. Conclusion
iFGF23 levels were significantly decreased prior to, and at 2 days
following pPCI in subjects with a first-time STEMI successfully
revascularized. iFGF23 levels normalized on day 7 in patients with-
out heart failure. There was a gradual increase in iFGF23 levels,
above normal levels, during one-year follow-up in patients with
signs and/or symptoms of heart failure during the acute phase of
the MI despite the use of aldosterone antagonist.Funding
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